ArticleMolecular diversity2026
Exploring OmpA of Orientia tsutsugamushi to design novel multi-epitope vaccine against scrub typhus: an immunoinformatics approach.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immuno-Informatics Design of Multi-Epitope Vaccine Candidate AgainstHealth science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Scrub typhus is a commonly neglected infectious febrile illness caused by an obligate intracellular bacterium known as Orientia tsutsugamushi. It is a major health problem, affecting one million people annually, and poses threat to one billion people worldwide. There is always the escalating threat posed by the development of antibiotic resistance in the forthcoming future which emphasizes on urgency of the development of vaccine against Orientia tsutsugamushi. Despite eight decades of research and development, currently there is no viable vaccine available against scrub typhus. Outer membrane protein A (OmpA) is highly conserved and immunogenic across 51 geographically diverse isolates of Orientia tsutsugamishi. The multi-epitope vaccine was constructed by integrating four B-cell, four MHC-I, and four MHC-II epitopes linked together using specific linkers. The cholera enterotoxin subunit B is linked with the vaccine construct at N-terminal as an adjuvant. The constructed vaccine is 329 amino acid long, highly antigenic, non-allergen, non-toxic, soluble and has 36.3 kDa molecular weight. The molecular docking of vaccine construct with TLR receptors showed strong binding affinity. The interactions among vaccine and TLR receptors were analyzed using PDBsum. The in silico immune simulation of constructed vaccine showed ability to trigger immune response as shown by augmentation in T-cell and B-cell population. The current study provides the way forward for controlling the febrile disease scrub typhus.
Indexed as
Identifiers
40632361What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.